title: Dipeptidyl peptidase-4 inhibitors and angioedema: a class effect?
abstract: BACKGROUND
  Dipeptidyl peptidase-4 (DPP-4) inhibitors have been reported to be generally well tolerated. However, angioedema has been reported as one of the rare adverse events of these drugs.
  
  
  METHODS
  We report a case in which angioedema induced by vildagliptin disappeared after changing to another DPP-4 inhibitor, alogliptin.
  
  
  CONCLUSIONS
  Our case suggests that there is a difference in the risk of angioedema among DPP-4 inhibitors. To clarify this possibility, further investigation on the risk of angioedema among DPP-4 inhibitors is warranted.
authors: Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan. ysaisho@z5.keio.jp
authors: Y
authors: Y
authors: Saisho
authors: H
authors: H
authors: Itoh
mesh_terms: D000218:Adamantane / Q000009:adverse effects / Q000031:analogs & derivatives*; D000368:Aged; D000799:Angioedema / Q000139:chemically induced*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000009:adverse effects*; D057915:Drug Substitution; D006801:Humans; D008297:Male; D009570:Nitriles / Q000009:adverse effects*; D010880:Piperidines / Q000627:therapeutic use; D011759:Pyrrolidines / Q000009:adverse effects*; D014498:Uracil / Q000031:analogs & derivatives / Q000627:therapeutic use; D000077597:Vildagliptin
chemical_list: D054873:Dipeptidyl-Peptidase IV Inhibitors; D009570:Nitriles; D010880:Piperidines; D011759:Pyrrolidines; D014498:Uracil; D000077597:Vildagliptin; C520853:alogliptin; D000218:Adamantane